North America Monoclonal Antibody Therapy Market Size, Share, Trends, COVID-19 impact & Growth Analysis Report – Segmented By Type (Human mAb, Humanized mAb, Chimeric mAb, Murine mAb), Application, Distribution channel, and country (United States, Canada and Rest of North America) - Industry Analysis From 2026 to 2034
The North America monoclonal antibody therapy market size was valued at USD 87.17 billion in 2025 and is anticipated to reach USD 100.78 billion in 2026 from USD 321.62 billion by 2034, growing at a CAGR of 15.61% during the forecast period from 2026 to 2034.
Monoclonal antibody (mAb) therapy is a form of targeted biological treatment that utilizes laboratory-produced molecules designed to mimic the immune system's ability to fight harmful pathogens, including cancer cells and autoimmune disease triggers. Monoclonal antibodies are increasingly being used in therapeutic applications such as oncology, immunology, infectious diseases, and rare disorders.
The increasing incidence of chronic and autoimmune diseases in the aging population is fuelling the growth of the North America monoclonal antibody therapy market. Conditions such as rheumatoid arthritis, psoriasis, Crohn’s disease, and systemic lupus erythematosus require long-term management, often involving biologic therapies like monoclonal antibodies that offer higher efficacy compared to traditional small-molecule drugs. According to the Centers for Disease Control and Prevention (CDC), approximately 60% of adults in the U.S. live with at least one chronic disease, and autoimmune diseases affect an estimated 23.5 million Americans, with numbers rising steadily. The prevalence of autoimmune diseases has increased significantly over the past decade, which is driven by environmental factors, genetic predispositions, and improved diagnostic techniques. For instance, the American College of Rheumatology reports that the number of diagnosed cases of rheumatoid arthritis alone has risen by nearly 10% since 2018. Moreover, the expansion of indications for existing monoclonal antibodies has broadened their usage across different disease states.
The technological advancements in biotechnology in the fields of recombinant DNA technology, protein engineering, and biomarker discovery, have significantly accelerated the development and commercialization of monoclonal antibody therapies in North America. These innovations have enabled the creation of highly specific antibodies tailored to individual patient profiles, fueling the growth of personalized medicine. According to the National Institutes of Health (NIH), the number of clinical trials related to monoclonal antibodies and personalized therapeutics has grown by over 15% annually between 2019 and 2024. Notably, the integration of artificial intelligence (AI) and machine learning into drug discovery processes has shortened development timelines and enhanced target specificity. Additionally, the rise of companion diagnostics tools used to identify patients most likely to benefit from a particular therapy has played a pivotal role in expanding the monoclonal antibody market. As reported by the Personalized Medicine Coalition, approximately 40% of newly approved oncology drugs between 2015 and 2023 included a companion diagnostic, many of which were monoclonal antibody-based treatments.
The high development and treatment costs pose a significant restraint on the North America monoclonal antibody therapy market growth. Developing a single monoclonal antibody can cost pharmaceutical companies upwards of $1 billion, according to estimates from the Tufts Center for the Study of Drug Development. In addition to development expenses, the final price of monoclonal antibody therapies remains prohibitively expensive for many patients and payers. Moreover, payer pushback against high-cost biologics has intensified in recent years. A 2023 survey by the Kaiser Family Foundation found that nearly 60% of U.S. health insurers imposed prior authorization requirements or step therapy protocols for monoclonal antibody prescriptions, aiming to control costs.
The growing influx of biosimilars and the expiration of key patents for blockbuster mAbs is restricting the growth of the North America monoclonal antibody therapy market. Biosimilars highly similar versions of reference biologics are typically priced 20–30% lower than their originator counterparts, creating intense price competition and eroding revenues for branded products. For example, Humira (adalimumab), once the world’s top-selling drug, lost patent exclusivity in late 2023, paving the way for over a dozen biosimilar competitors. Patent expirations for other major mAbs, including Remicade (infliximab) and Rituxan (rituximab), have already led to substantial revenue declines for their original developers. The shift toward biosimilars, while beneficial for cost containment, reduces the profitability of innovator companies and may deter future R&D investments unless offset by pipeline innovation or market exclusivity extensions through formulation improvements or new indications.
The expansion of indications for existing drugs and the robust pipeline of novel monoclonal antibodies targeting unmet medical needs is attributed in escalating the growth of the North America monoclonal antibody therapy market. Pharmaceutical companies are increasingly repurposing approved monoclonal antibodies for additional disease conditions, thereby extending their lifecycle and maximizing return on investment. As per the U.S. National Library of Medicine’s ClinicalTrials.gov database, there are over 1,500 active clinical trials involving monoclonal antibodies in North America alone, with more than 300 in Phase III as of mid-2024. Many of these trials are exploring applications beyond traditional oncology and autoimmune uses, including neurology, cardiology, and rare diseases. Additionally, the expansion of label indications for established therapies has contributed to revenue diversification.
The integration of digital health technologies into the delivery and monitoring of monoclonal antibody therapies is additionally to fuel the growth of the market in North America. Innovations such as connected infusion pumps, wearable biosensors, and mobile health platforms are enabling real-time patient monitoring, improving adherence, and facilitating remote care for self-administered injectable mAbs. According to a 2024 report by Deloitte, over 70% of surveyed biopharma companies are investing in digital companion tools for injectable biologics, including monoclonal antibodies. These tools enhance patient engagement by providing dose tracking, side-effect reporting, and telehealth connectivity. For example, Sanofi’s partnership with Propeller Health to develop smart injection devices for Dupixent users aims to improve medication adherence and clinical outcomes.
Moreover, the Centers for Medicare & Medicaid Services (CMS) expanded reimbursement for digital therapeutics and remote monitoring services in 2023, aligning with broader efforts to digitize healthcare delivery. This policy shift encourages providers to integrate digital solutions alongside monoclonal antibody therapies in managing chronic conditions such as rheumatoid arthritis and multiple sclerosis.
Additionally, artificial intelligence-powered analytics platforms are being used to predict adverse events and personalize dosing regimens. A study published in Nature Biotechnology in 2023 demonstrated how AI models could reduce infusion-related reactions by up to 25% through predictive analytics, enhancing safety and patient experience.
The regulatory complexity and prolonged approval timelines present a significant challenge to the growth of the North America monoclonal antibody therapy market. The U.S. Food and Drug Administration (FDA) maintains strict guidelines under the Biologics License Application (BLA) framework, which can delay market entry and increase compliance costs. According to a 2023 analysis by the FDA’s Office of Biotechnology Products, the median review time for monoclonal antibody BLAs was 14.2 months, with some applications taking over two years due to requests for additional data or manufacturing clarifications. Furthermore, evolving regulatory expectations around biosimilarity, immunogenicity assessments, and post-marketing surveillance add layers of complexity. In 2022, the FDA issued updated guidance on analytical similarity thresholds for biosimilars, prompting several manufacturers to rework formulations or conduct supplementary studies. These hurdles increase development timelines and capital expenditures, potentially deterring smaller biotech firms from entering the market.
The manufacturing scalability and supply chain is also to inhibit the growth of the North America monoclonal antibody therapy market. Monoclonal antibodies are produced using living cells typically Chinese hamster ovary (CHO) cell lines in bioreactors under highly controlled conditions. This process is inherently complex, time-consuming, and sensitive to variations in raw materials, facility capacity, and quality control standards. North America, being a major hub for biologics manufacturing, felt the impact acutely, with several companies experiencing delays in scaling up production for new mAbs. Additionally, the high cost and limited availability of specialized contract manufacturing organizations (CMOs) capable of handling large-scale mAb production pose barriers to timely commercialization.
The humanized monoclonal antibody segment was the largest and held 45.3% of the North America monoclonal antibody therapy market share in 2024 with the increasing adoption of humanized mAbs in chronic disease management, particularly in oncology and autoimmune disorders. Moreover, biopharmaceutical companies are focusing on developing next-generation humanized antibodies with enhanced target specificity and reduced side effects. A study published in mAbs, a peer-reviewed journal, noted that over 60% of all monoclonal antibodies approved by the FDA between 2018 and 2023 were either humanized or fully human.
The human monoclonal antibody segment is projected to grow with a CAGR of 12.3% during the forecast period due to the rising preference for human mAbs in oncology and infectious disease treatment due to their superior safety profiles and minimal immune response. For instance, the FDA-approved human mAb casirivimab/imdevimab (REGEN-COV) for emergency use in mild-to-moderate COVID-19 showed high efficacy with low adverse event rates, as documented in clinical trials conducted by Regeneron Pharmaceuticals in 2022. Additionally, the expanding pipeline of human mAbs targeting rare diseases and orphan indications has contributed to increased investment in this segment. According to the Biotechnology Innovation Organization (BIO), approximately 35% of all mAb-based therapies in Phase III clinical trials in North America as of 2024 were fully human.
The oncology application segment dominated the North America monoclonal antibody therapy market by capturing 52.3% of the share in 2024 with the rising incidence of various cancers, especially hematologic malignancies and solid tumors, which require advanced biological interventions. According to the American Cancer Society, an estimated 1.9 million new cancer cases were diagnosed in the U.S. in 2023 alone, with non-Hodgkin lymphoma, breast cancer, and colorectal cancer among the most prevalent types where monoclonal antibodies play a crucial role. Furthermore, the expansion of indications and the approval of novel antibody-drug conjugates (ADCs) like Enhertu and Trodelvy have reinforced the dominance of oncology within the monoclonal antibody market by ensuring continued growth in this therapeutic area.
The autoimmune diseases segment is anticipated to register a CAGR of 13.5% in the coming years with the shift toward biologic therapies over traditional small-molecule drugs due to their superior efficacy and targeted mechanism of action. Additionally, the launch of newer generation anti-IL-17, anti-IL-23, and JAK-inhibitor monoclonal antibody therapies has broadened treatment options and improved patient outcomes.
The hospital pharmacy segment held a dominant share of the North America monoclonal antibody therapy market in 2024 due to the intravenous (IV) administration route of most monoclonal antibodies, which necessitates infusion services typically provided in hospital settings. Additionally, hospital pharmacies benefit from direct procurement contracts with manufacturers and group purchasing organizations (GPOs), enabling cost-effective acquisition of high-cost biologics. The Healthcare Supply Chain Association (HSCA) notes that GPOs facilitate over 90% of hospital pharmaceutical purchases in the U.S., giving hospital pharmacies preferential pricing and supply stability for monoclonal antibody therapies.
The online pharmacy segment is projected to exhibit a CAGR of 14.8% from 2025 to 2033, with the increasing availability of subcutaneous and self-administered monoclonal antibody formulations, coupled with rising consumer preference for digital healthcare solutions. The introduction of home-based delivery programs for injectable mAbs is leveraging the growth of the segment. For instance, Dupixent (dupilumab), which is indicated for atopic dermatitis and asthma, is widely dispensed through specialty online pharmacies that offer mail-order services, nurse training, and adherence support. Additionally, the expansion of telehealth services and digital prescribing platforms has streamlined access to monoclonal antibody therapies.
The United States was the top performer of the North America monoclonal antibody therapy market with 85.3% of the share in 2024. The country hosts the majority of global monoclonal antibody developers, including industry giants such as AbbVie, Amgen, Genentech (a Roche subsidiary), and Johnson & Johnson. These companies account for a significant portion of mAb approvals and commercial launches, with the FDA approving over 25 new monoclonal antibody therapies between 2020 and 2023, as reported by the U.S. Food and Drug Administration. Additionally, the U.S. benefits from a well-established reimbursement framework, particularly through private insurers and Medicare Part B, which covers infused monoclonal antibodies administered in outpatient settings. However, rising cost pressures and payer restrictions have prompted discussions around value-based pricing models, influencing market dynamics.
Canada monoclonal antibody therapy market was positioned second by holding 18.3% of share in 2024. The increasing adoption of monoclonal antibodies in treating autoimmune and oncologic conditions is fuelling the growth of the market in this country. According to Statistics Canada, the number of Canadians living with rheumatoid arthritis rose to 628,000 in 2023, up from 580,000 in 2020. Similarly, the Canadian Cancer Society reports that over 230,000 new cancer cases were diagnosed in 2023, many of which involved monoclonal antibody-based treatment strategies.
The competition in the North America monoclonal antibody therapy market is intense and highly dynamic, driven by a convergence of global pharmaceutical giants, emerging biotech firms, and biosimilar developers. Established players leverage their strong R&D pipelines, established brand portfolios, and deep-rooted distribution networks to maintain dominance. At the same time, smaller biotech companies are increasingly disrupting the market by introducing niche, targeted therapies that address unmet medical needs. The growing influence of biosimilars is reshaping pricing strategies and forcing innovator companies to rethink their commercial approaches. Regulatory agility, payer dynamics, and evolving patient preferences further complicate the competitive landscape. Companies are under pressure to demonstrate value through real-world evidence, improve patient access, and integrate digital health tools into treatment pathways. Strategic mergers, acquisitions, and partnerships are becoming more common as firms seek to consolidate their positions, diversify offerings, and navigate an increasingly complex market environment.
Some of the dominating companies in the North America monoclonal antibody therapy market include
Nantong Egens Biotechnology Co., Ltd.
AbbVie Inc.
AbbVie is a leading player in the monoclonal antibody therapy market, known for its flagship product Humira (adalimumab), one of the most prescribed biologics globally before biosimilar entry. The company has consistently invested in expanding its immunology portfolio with newer therapies such as Skyrizi (risankizumab) and Rinvoq (upadacitinib).
Roche Holding AG (Genentech)
Roche, through its U.S.-based subsidiary Genentech, plays a pivotal role in shaping the monoclonal antibody landscape in North America. Its portfolio includes blockbuster mAbs like Herceptin, Rituxan, and Tecentriq, which are widely used in oncology and immunology. Roche continues to drive growth through extensive R&D investments, personalized medicine initiatives, and collaborations aimed at developing next-generation monoclonal antibodies and antibody-drug conjugates.
Amgen Inc.
Amgen has been instrumental in advancing monoclonal antibody therapies for chronic diseases, particularly in oncology and inflammatory conditions. With key products such as Blincyto, Aimovig, and a growing biosimilars pipeline, Amgen maintains a strong presence in the North American market. The company leverages its expertise in biotechnology and robust manufacturing capabilities to ensure a consistent supply and therapeutic innovation.
Continuous Innovation and Pipeline Expansion
Leading players prioritize research and development to discover novel monoclonal antibodies and expand indications for existing drugs. This approach ensures sustained relevance and revenue generation from both new launches and lifecycle management strategies.
Strategic Collaborations and Partnerships
Pharmaceutical firms frequently engage in alliances with biotech startups, academic institutions, and contract research organizations to accelerate drug discovery, share risks, and access cutting-edge technologies that enhance therapeutic development.
Biosimilar Development and Market Defense
With the expiration of key patents, companies are investing in biosimilar versions of rival drugs while
simultaneously developing differentiated formulations or next-generation therapies to retain market share and maintain competitive advantage.
This research report on the North America monoclonal antibody therapy market has been segmented and sub-segmented into the following categories:
By Type
By Application
By Distribution Channel
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region